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Abstract
Background In the Netherlands, a screening programme
was set up in 1994 in order to identify all patients with
familial hypercholesterolaemia (FH). After 15 years of
screening, we evaluated the geographical distribution,
possible founder effects and clinical phenotype of the 12
most prevalent FH gene mutations.
Methods Patients who carried one of the 12 most prevalent
mutations, index cases and those identified between 1994
and 2009 through the screening programme and whose
postal code was known were included in the study. Low-
density lipoprotein cholesterol (LDL-C) levels at the time
of screening were retrieved. The prevalence of identified
FH patients in each postal code area was calculated and
visualised in different maps.
Results A total of 10,889 patients were included in the
study. Mean untreated LDL-C levels ranged from 4.4 to
6.4 mmol/l. For almost all mutations, a region of high
prevalence could be observed. In total, 51 homozygous
patients were identified in the Netherlands, of which 13 true
homozygous for one of the 12 most prevalent mutations.
The majority of them were living in high-prevalence areas
for that specific mutation.
Conclusions Phenotypes with regard to LDL-C levels
varied between the 12 most prevalent FH mutations. For
most of these mutations, a founder effect was observed. Our
observations can have implications with regard to the
efficiency of molecular screening and physician’s percep-
tion of FH and to the understanding of the prevalence and
distribution of homozygous patients in the Netherlands.
Keywords Familial hypercholesterolemia.LDL
cholesterol.LDL receptor gene.ApoB gene.Genetic
screening.Founder effect.Homozygosity
Introduction
Familial hypercholesterolaemia (FH) is an autosomal co-
dominant monogenic disorder of lipoprotein metabolism. It
is characterised by severely elevated levels of low-density
lipoprotein cholesterol (LDL-C) from birth onwards,
clinically leading to premature atherosclerosis and cardio-
vascular disease (CVD). The estimated prevalence of
heterozygous FH is 1 per 400 in the Dutch population [1,
2]. Homozygosity is rare with an average frequency of
1:640,000.
FH is mainly caused by mutations in the LDL receptor
(LDLR) gene, encoding for a receptor that removes LDL-C
particles from the circulation and facilitates uptake by the
liver cell [3]. In approximately 7% of cases, the clinical
phenotype of FH is the result of mutations in the region of the
gene encoding for the LDLR-binding domain of apolipopro-
tein B (APOB)[ 4]. Also, gain-of-function mutations in the
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9( PCSK9), a protein that regulates LDL receptor degrada-
tion, are a rare cause (<1%) of the FH phenotype.
More than 1000 different mutations, assumed to cause an
FH phenotype, have been identified worldwide [5]. In the
Netherlands, 552 different mutations have been identified
so far. The specific mutations can vary with respect to
clinical severity, as observed by LDL-C levels [6],
atherosclerosis as assessed by carotid intima-media thick-
ness [7] as well as by prevalence of CVD [8]. In some
populations, the majority of cases of FH can be explained
by only a few mutations, and a founder effect usually
underlies a higher than expected frequency of certain
mutations.
The importance of early diagnosis and management of
FH is well established, and therefore, screening for FH is
advocated [9]. In the Netherlands, approximately 20,000
subjects have been identified with a pathogenic FH
mutation so far, mostly through a nationwide genetic
cascade screening programme. Because FH has been
studied this extensively in our country, this enables us to
study some interesting aspects with regard to geographical
distribution and prevalence of homozygous patients not
directly related to consanguinity. In this study, we explored
the geographical distribution, possible founder effects and
clinical phenotype with regard to LDL-C levels of the 12
most prevalent FH mutations in the Netherlands.
Patients and Methods
Selection of Study Population
In the Netherlands, genetic cascade screening is carried
out by the Foundation for Identification of Persons with
Inherited Hypercholesterolaemia (in Dutch: StOEH).
Physicians clinically diagnose patients suspected of
having FH using uniform diagnostic criteria after which
extensive DNA analysis is performed [10]. Once a
mutation is identified, the patient is designated as an
index case. Cascade screening is then performed to test all
first-degree family membe r s ,a n di fp o s i t i v ef o rt h e
familial mutation, more distant relatives are tested to
expand the pedigree [11]. Since 2003, lipid levels are
measured at the time of genetic testing with a Cholestech
LDX analyser [12].
Patients with one of the 12 most prevalent FH mutations,
index cases and those identified between 1994 and 2009
through cascade screening and whose postal code was
known were included in the study. In order to prevent
Table 1 Nomenclature and characteristics of the 12 most common mutations
Common name
a Official name
b N (% of total) Gene Subjects with known LDL-C
c Untreated subjects
d
N LDL-C pLDL N LDL-C pLDL
N543H/2393del9bp p.Asn564His/c.2393del9 2299 (17.4) LDLR 1141 5.0±1.5 88 724 4.4±1.2 87
R3500Q p.Arg3527Gln 1653 (12.5) APOB 1328 4.9±1.5 87 875 4.3±1.1 84
1359-1 c.1359-1 G>A 979 (7.4) LDLR 478 6.2±2.1 92 181 5.2±1.6 91
313+1/2 c.313+1 G>C/c.313+2 T>C 844 (6.4) LDLR 491 6.2±2.0 93 244 5.4±1.4 92
W23X p.Trp44X 472 (3.6) LDLR 268 6.2±1.8 93 132 5.6±1.6 93
S285L p.Ser306Leu 466 (3.5) LDLR 276 5.1±1.4 91 180 4.8±1.3 91
E207K p.Glu228Lys 437 (3.3) LDLR 276 6.3±2.3 93 120 5.3±1.4 95
2.5 kb del (Cape Town-2) c.941-?_c.1186+? del 295 (2.2) LDLR 163 6.4±2.4 94 74 5.2±1.4 94
191-2 c.191-2A>G 271 (2.1) LDLR 197 6.4±2.4 94 79 5.3±1.3 94
G322S p.Gly343Ser 236 (1.8) LDLR 212 4.4±1.5 79 140 3.9±1.0 75
G186G p.Gly207Gly 218 (1.7) LDLR 246 5.2±1.7 89 131 4.5±1.2 89
V408M p.Val429Met 192 (1.5) LDLR 82 6.1±1.8 93 44 5.4±1.5 91
LDL-C levels (millimoles per litre) are expressed as mean±standard deviation, pLDL-C mean percentile for age and gender
N number, not including index cases, LDLR low-density lipoprotein receptor, APOB apolipoprotein B, LDL-C low-density lipoprotein cholesterol
aCommon name representing numbering of the codons with initiation codon is −21 for LDLR and −27 for APOB
bOfficial name representing numbering of the codons with the initiation codon is 1 [28]
cAll subjects, identified through the screening programme, of which LDL-C was measured at the moment of genetic screening (done since 2003); for
subjects on lipid-lowering medication, pre-treatment LDL-C levels were estimated with correction for treatment potency [15]
dSubjects identified through the screening programme without lipid-lowering medication at the moment of genetic testing
Fig. 1 Geographical distribution of the 12 most common FH
mutations in the Netherlands, index cases only. Number of patients
identified with the specific mutation, adjusted for resident number of
concerning PC2 code area per million (between brackets, number of
PC2 code areas)

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active in referring cases for DNA analysis [13, 14], index
cases and family members identified through the screen-
ing programme were studied separately. Mean LDL-C
levels and mean percentile LDL-C for age and gender at
the time of screening were only retrieved for patients
identified though the screening programme, as these data
were not routinely provided for index cases. When
patients were on lipid-lowering medication, LDL-C levels
were imputed by the estimated LDL-C lowering potency
of a specific lipid-lowering drug and dose, as described
by Huijgen et al. [15].
Index cases and carriers who were homozygous for a
certain mutation were identified in the database of the DNA
diagnostic laboratory of the Academic Medical Centre
(AMC) at the University of Amsterdam.
Distribution Across Postal Code Areas
In the Netherlands, geographic areas are defined by so-
called PC2 codes, in which the first two of four digits of the
postal code determine a geographic region. The mean
number of inhabitants of a postal code area is 180,000
(range, 35,170 to 652,685). The number of identified FH
patients in each PC2 area was reproduced as prevalence per
million, adjusted for inhabitant number of that area. The
prevalence of the 12 mutations in each PC2 area has been
visualised with the software of Mapinfo Professional
(Mapinfo, Toronto, Canada). The locations where homozy-




A total of 4861 index cases with 552 different pathogenic
mutations were identified in the DNA database of the
AMC. Of these, 528 were in LDLR (88%) and 25 in APOB
(12%) mutations. Hitherto, mutations in PCSK9 that result
in a FH phenotype have not been identified in the
Netherlands. Between 1994 and 2009, 14,805 patients with
FH were identified through the genetic cascade screening
programme. The 12 most common mutations were respon-
sible for 64% of all FH patients, including 2699 index cases
and 9393 patients identified through the screening
programme. The patients with a known postal code (2527
index cases and 8362 patients from the screening
programme) were included in the study.
Characteristics of the 12 most common mutations in
patients identified through the screening programme are
summarised in Table 1. Mean untreated LDL-C levels
ranged from 3.9 to 5.6 mmol/l between mutations. Together
with the estimated pre-treatment LDL-C levels in the
patients on lipid-lowering medication, these levels were
higher and the differences more pronounced, ranging from
4.4 to 6.4 mmol/l.
Geographical Distribution of FH Mutations
in the Netherlands
The prevalence per PC2 area is illustrated for each mutation
in Fig. 1 for the index cases and in Fig. 2 for patients
identified through the screening programme. The most
common mutation, the N543H/2393del9bp, was by far
most frequent in West Friesland (a contemporary region in
the North West of the Netherlands), with a prevalence of
2860 per million, which is similar to 1:349. The R3500Q
mutation in APOB was the second most common mutation
and was distributed about equally over the Netherlands; it
was the only mutation present in each of the 90 PC2 areas.
Mutations with a high prevalence (index cases included) in
only one or two PC2 code areas included 1359-1 in the
province of Brabant in the South (1548 per million≈1:646 for
the most dense area), 191-1 in the province of Zeeland in the
south-western part (1151 per million≈1:869 for the area
known as Noord and Zuid Beveland), the E207K mutation
concentrated in the western part of the Netherlands (498–707
per million in the two most dense areas) and the 2.5-kb
deletion of exons 7–8 also in the province of Brabant (207–
257 per million in the two most dense areas).
For the total prevalence of the 12 most frequent
mutations together (Figs. 3 and 4), the PC2 areas with the
highest prevalence were West Friesland (1:280), predomi-
nantly resulting from N543H/2393del9bp (82%), R3500Q
(8%) and V408M (4%) mutation, and the islands Noord
and Zuid Beveland in the province of Zeeland (1:329),
mainly resulting from 191-2 (37%), 313+1/2 (18%), 1359-
1 and G322S (both 5%) mutation. The lowest prevalence
was found in the north of the province of Limburg in the
south-eastern part of the Netherlands (1:6803) and in the
east of the province of Overijssel, in the mid-eastern part of
the Netherlands (1:6061).
Homozygous FH Patients
In total, 51 patients were identified as suffering from
homozygous FH, of which 27 were compound heterozy-
gotes and 24 were true homozygotes. Of the true
homozygous patients, 13 were homozygous for one of the
Fig. 2 Geographical distribution of the 12 most common FH
mutations in the Netherlands, index cases excluded (arrows indicate
homozygous patients). Number of patients identified with the specific
mutation, adjusted for resident number of concerning PC2 code area
per million (between brackets, number of PC2 code areas)

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heterozygous patients, one of these mutations was involved.
As shown in Fig. 2, almost all true homozygous patients
were living in high-prevalence areas for that specific
mutation.
Discussion
In the Netherlands, a national screening programme for FH
is ongoing and has yielded the largest genotyped FH
population worldwide. For this study, we determined the
geographical distribution of the 12 most common muta-
tions, which represent 64% of all Dutch FH patients. We
demonstrated that almost all common mutations showed a
clearly marked region of preference, suggesting the
existence of a founder effect. This can be explained by
the occurrence of a local founder mutation in combination
with limited migration, possibly attributable to the geo-
graphical isolation in the past, as in West Friesland and the
islands of Noord and Zuid Beveland, the two regions with
the highest prevalence of mutations per se. The phenome-
non of geographical preference of FH causing mutations
can have several clinical implications.
Firstly, knowledge of the prevalence of a certain
mutation can be used in strategies for molecular testing;
when a mutation predominates in a region, molecular tests
can be designed to identify these specific variant alleles
first. Secondly, knowledge of mutation distribution may
explain the identification of homozygous patients in non-
consanguineous families. This has been confirmed by our
finding that most of the true homozygous patients are found
in regions with a high prevalence of that specific mutation
and the fact that the total number of identified homozygous
patients (51) is higher than the expected number of 26
(1:640,000 in 16.5 million people in the Netherlands).
Thirdly, our observations can influence the perception of
physicians in different regions with regard to the prevalence
of FH and the severity of the FH phenotype in their region.
It is not unlikely that physicians in the north-western region
where the relatively mild N543H/2393del9bp mutation is
most prevalent have a different perception of CVD risk
attributable to FH than colleagues in the south of the
Netherlands where the severe 1359-1 mutation predom-
inates. The latter is known for its significantly higher LDL-
C levels and higher incidence of premature CVD. The
relative risk of coronary artery disease in FH patients
compared with unaffected relatives was found to be 7.83
Fig. 3 Geographical distribution of the 12 most common FH
mutations together, index cases only. Number of patients identified
with one of the 12 most common mutations, adjusted for resident
number of concerning PC2 code area per million (between brackets,
number of PC2 code areas)
Fig. 4 Geographical distribution of the 12 most common FH
mutations together, index cases excluded. Number of patients
identified with one of the 12 most common mutations, adjusted for
resident number of concerning PC2 code area per million (between
brackets, number of PC2 code areas)
180 Neth Heart J (2011) 19:175–182(95% CI, 3.11–19.67) for carriers of the N543H/2393del9
mutation and 15.95 (95% CI, 5.52–46.14) for carriers of the
1359-1 mutation [16].
Dutch FH patients share mutations with FH populations
in other countries, as discussed by Fouchier et al. [3, 17].
This can be partly explained by the migration of individuals
over Europe during the last centuries, demonstrated by
large numbers of similar mutations in neighbouring
countries such as Germany, the UK, Belgium and Denmark
[3]. However, detection rates of mutations depend on the
intensity of screening in different countries, and the global
array of mutations is therefore not complete.
T o w n sw i t hh a r b o u r st h a ts e r v e da sa no u t p o s tf o rt r a d i n g
with other coastal communities may have been the source of
the spread of the prevalent mutations in those regions. A
mutation of special interest in that respect is the V408M
mutation, which is most commonly found in West Friesland,
close to the former Zuiderzee (now a lake, but it used to be
connected to the North Sea). This is one of the regions from
where settlers to South Africa departed in the seventeenth
century, with important port towns as Hoorn and Enkhuizen.
TheV408MmutationisoneofthefoundermutationsinSouth
Africa, present in 15–20% of the South African Afrikaner FH
patients [18]. It has been suggested that this was the result of
Dutch migration, in times of the expeditions of the Dutch
colonial administrator Jan Van Riebeeck, the founder of
Cape Town in the seventeenth century. It was indeed
established that some of the Dutch FH patients shared the
same haplotype with an Afrikaner, who was homozygous for
this mutation [19]. Furthermore, it has been suggested that
this mutation was also introduced in Canada at the beginning
of the twentieth century by the large immigration waves
from (the northern part of) the Netherlands. The founder of a
Canadian FH family with the V408M mutation was traced
back to Andijk [20], which is also situated in West Friesland.
By comparing mutation frequencies within and between
populations, insight into the evolutionary history of genes
and populations can be gained. It has been found that
almost all FH patients with R3500Q (showing no founder
effect in the Netherlands and present in different popula-
tions over the world) share the same rare haplotype.
Therefore, it is postulated that the first original R3500Q
mutation occurred approximately 6750 years ago [21, 22].
However, it is also possible that some mutations occurred
on multiple occasions, referred to as recurrent mutations.
For instance, ‘Dutch’ mutations are also found in countries
as Japan, which is geographically isolated and Japanese
people are believed to be uniracial [23]. The same applies
for some mutations found in rural China [24].
Currently, more than 550 different FH mutations have
been identified in the Netherlands, from which 471 have
been used in cascade screening. These numbers are
different because not all patients had given consent for
family screening. In populations where one or two
mutations predominate, founder effects are much more
pronounced than in the Netherlands. In Finland, four
different mutations are responsible for 75% of FH patients,
which can be explained by the unique geographical position
of Finland between Eastern and Western cultures as well as
by linguistic barriers [25]. Other examples of populations
with a clear founder effect are the French-Canadians, with
the 10-kb deletion in 60% of patients and a total FH
prevalence of about 1:200 [26], and the earlier mentioned
South African Afrikaners, where three founder mutations
are responsible for 95% of all Afrikaner FH patients
(including the ‘Dutch’ V408M mutation), and an estimated
prevalence for FH of 1:72 [27]. As in these populations, this
study showed that also in the Dutch population, founder
effects result in high prevalence in certain regions, in
particular in the area of West Friesland, where a prevalence
of1:280was found,which ishigherthanthe overall estimated
prevalence for the Netherlands [2]. It has to be taken into
account that patients without a known postal code were
excluded from our analysis (approximately 7% for index
cases and 12% for other patients), that only the data of the 12
most frequent mutations were used, and that all patients
might not have been traced yet, so in fact the real prevalence
for this area could be considerably higher. For instance, the
area with the highest prevalence of index cases (825 per
million) is the islands of Noord and Zuid Beveland. From the
experience of the screening programme, we know that
through one index case, approximately eight family members
with FH can be traced [14]. This would mean that by adding
up the 7% with an unknown postal code, the prevalence for
the 12 most common mutations in this area can be estimated
to be 1:142.
Efficacy of identification of FH patients through a
cascade screening programme such as in the Netherlands
is dependent on several factors: regional referral rate,
regional coverage of the screening programme, family size
and willingness of relatives to participate. All these factors
may have influenced the results of our study. We attempted
to reduce referral bias of physicians by analysing index
cases and identified family members separately, but as
almost similar patterns can be observed in the two figures,
this appears to play a minor role. Our results show different
distributions for all 12 mutations with dense areas in all
parts of the country, which reflects nationwide coverage.
Estimations of the percentage of traced FH patients differ
among provinces [14], but these are based on a presumed
even distribution. Furthermore, we assume that family size
and willingness for screening are similar for different
mutations. Although these assumptions may not be com-
pletely correct and therefore may have biased our results to
some extent, we have found a clear, unique distribution for
the 12 most prevalent mutations.
Neth Heart J (2011) 19:175–182 181Conclusion
Although more than 550 different FH mutations are identified
in the Netherlands, for most of the 12 most prevalent Dutch
mutations a founder effect can be observed, resulting in
differences in geographical prevalence across the Nether-
lands. This can be explained by local founder effects plus
limited migration, which is also reflected by the fact that
neighbouring countries and countries were Dutch immigrants
usedtogo,sharethesamemutations.Thehighprevalenceand
typical distribution of Dutch homozygous patients can also be
understood by these founder effects. Molecular screening can
be more efficient if it is tailored to the allele frequency
distributionoftheDutchpopulation.Furthermore,physician’s
perception of FH could be influenced by the severity of the
phenotypeofthemostprevalentmutationinacertainarea,but
further research is needed to confirm this.
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